ASPN has been identified as a novel mesenchymal stromal cell factor that affects tumor microenvironment and metastatic progression (Hughes et al., 2019), including prostate cancer (Hurley et al., 2016), breast cancer (Maris et al., 2015), colorectal cancer (Huang C. Z et al., 2022), and others. Here, ASPN is linked to prostate cancer.